Tiba will be responsible for managing named-patient requests through which physicians can legally and ethically prescribe Apealea for patients prior to commercial availability, commercialize and distribute the product throughout the Middle East and North African region.
Therapeutic Area: Oncology Product Name: Apealea
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Elevar Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2020